Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Food Allergenic Extract [EPC]
Pulsatilla Patens Whole is a non-standardized plant allergenic extract used primarily in the diagnosis and treatment of specific plant-related allergies through immunotherapy.
Name
Pulsatilla Patens Whole
Raw Name
PULSATILLA PATENS WHOLE
Category
Non-Standardized Food Allergenic Extract [EPC]
Drug Count
6
Variant Count
6
Last Verified
February 17, 2026
About Pulsatilla Patens Whole
Pulsatilla Patens Whole is a non-standardized plant allergenic extract used primarily in the diagnosis and treatment of specific plant-related allergies through immunotherapy.
Detailed information about Pulsatilla Patens Whole
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Pulsatilla Patens Whole.
Pulsatilla Patens Whole belongs to a class of drugs called Allergenic Extracts. These substances are biological products used for 'hyposensitization' or 'immunotherapy.' The goal of using these extracts is to gradually desensitize a patient's immune system to a specific allergen, thereby reducing the severity of allergic symptoms upon future exposure. Historically, the use of plant extracts for medicinal purposes dates back centuries, but their refinement into sterile, injectable forms for allergy testing and treatment represents a cornerstone of modern clinical immunology.
The mechanism of action for Pulsatilla Patens Whole as an allergenic extract is rooted in the modulation of the human immune system. When a patient is allergic to a substance, their immune system overreacts by producing Immunoglobulin E (IgE) antibodies specific to the proteins found in that substance. When these IgE antibodies encounter the allergen again, they trigger mast cells and basophils (types of white blood cells) to release inflammatory mediators like histamine, leukotrienes, and cytokines, leading to the symptoms of an allergic reaction.
Pulsatilla Patens Whole works through a process called Allergen Immunotherapy (AIT). When administered in small, escalating doses, the extract induces a shift in the immune response. Specifically, it encourages the production of Immunoglobulin G4 (IgG4), often referred to as 'blocking antibodies.' These IgG4 antibodies compete with IgE for the allergen binding sites, preventing the allergic cascade. Furthermore, long-term administration leads to a shift from a Th2-dominated immune response (which promotes allergy) to a Th1-dominated response, and increases the activity of Regulatory T cells (Tregs), which secrete anti-inflammatory cytokines like IL-10 and TGF-beta.
Because Pulsatilla Patens Whole is a complex biological extract administered via subcutaneous (under the skin) injection or intradermal (into the skin) testing, its pharmacokinetics differ significantly from traditional synthetic drugs.
Pulsatilla Patens Whole is primarily indicated for two clinical purposes:
Pulsatilla Patens Whole is typically available in the following forms:
> Important: Only your healthcare provider can determine if Pulsatilla Patens Whole is right for your specific condition. Immunotherapy should only be conducted under the supervision of a board-certified allergist or immunologist prepared to treat systemic allergic reactions.
Dosage for Pulsatilla Patens Whole is highly individualized and must be determined by a physician based on the patient's sensitivity levels, which are often assessed via skin testing. There is no 'standard' dose because this is a non-standardized extract.
Pulsatilla Patens Whole is generally considered safe for use in children, provided they are old enough to cooperate with the injection schedule and communicate symptoms of a reaction. Dosing follows the same weight-to-volume titration logic as adult dosing. However, extra caution is required in children with unstable asthma, as they are at higher risk for severe reactions. Clinical guidelines often suggest that immunotherapy is most effective when started early in the progression of allergic disease.
Specific dosage adjustments for renal (kidney) impairment have not been established for allergenic extracts. Because the proteins are metabolized by proteases, renal function is generally not a limiting factor for dosing, though overall health status should be considered.
No specific adjustments are required for patients with hepatic (liver) impairment. The clearance of allergenic proteins does not rely on the cytochrome P450 system.
Elderly patients may be at higher risk for complications if a systemic reaction occurs, especially if they have underlying cardiovascular disease. Healthcare providers may choose a more conservative build-up schedule for patients over age 65.
If a dose is missed during the build-up phase, the next dose may need to be reduced to prevent a reaction. If a dose is missed for more than 2-4 weeks during the maintenance phase, the physician will typically 'backtrack' to a lower concentration and re-titrate upward. Never attempt to 'double up' on doses to make up for a missed appointment.
An 'overdose' in the context of allergenic extracts usually refers to an injection of a concentration that is too high for the patient's current level of tolerance.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip appointments without medical guidance, as this increases the risk of a reaction.
Most patients undergoing immunotherapy with Pulsatilla Patens Whole will experience some form of local reaction. These are generally not dangerous but can be uncomfortable.
> Warning: Stop taking Pulsatilla Patens Whole and call your doctor immediately or seek emergency care if you experience any of these symptoms of Anaphylaxis:
There are no known long-term 'toxic' side effects associated with the chronic use of Pulsatilla Patens Whole. Unlike corticosteroids or other immunosuppressants, allergenic extracts do not cause organ damage or systemic immunosuppression. The primary long-term 'effect' is the desired desensitization of the immune system. In rare cases, some patients may develop 'serum sickness' (a delayed immune complex reaction), though this is more common with animal-derived serums than with plant extracts.
Allergenic extracts, including Pulsatilla Patens Whole, carry a class-wide FDA Black Box Warning regarding the risk of severe, life-threatening systemic reactions.
Report any unusual symptoms or delayed reactions (occurring hours after the injection) to your healthcare provider immediately.
Pulsatilla Patens Whole is a potent biological substance. It is intended for use only by physicians experienced in the administration of allergenic extracts. Patients must be informed that the risk of a systemic reaction is always present, even if they have tolerated previous injections without issue.
No FDA black box warnings specifically unique to Pulsatilla Patens Whole exist beyond the standard class-wide warning for all allergenic extracts. This warning emphasizes that the extract can cause severe anaphylaxis and must be administered in a clinical setting equipped with emergency resuscitative equipment and epinephrine. Patients with severe, unstable, or steroid-dependent asthma are at the highest risk for a fatal outcome should a reaction occur.
There are no specific laboratory tests (like blood counts or liver panels) required for Pulsatilla Patens Whole. However, clinical monitoring is rigorous:
Generally, Pulsatilla Patens Whole does not impair the ability to drive. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive until cleared by a medical professional. Some patients may feel lightheaded or fatigued after an injection and should wait until they feel fully alert.
Alcohol consumption should be avoided for several hours before and after an injection. Alcohol can cause vasodilation (widening of blood vessels), which may theoretically increase the rate of allergen absorption and potentially worsen the severity of an allergic reaction.
There is no 'withdrawal syndrome' associated with stopping Pulsatilla Patens Whole. However, if treatment is discontinued prematurely, the patient's allergy symptoms are likely to return. If a patient decides to stop immunotherapy, they should discuss an alternative management plan with their allergist.
> Important: Discuss all your medical conditions, especially respiratory or heart problems, with your healthcare provider before starting Pulsatilla Patens Whole.
There are no direct food interactions with Pulsatilla Patens Whole. However, patients should avoid heavy meals or vigorous exercise immediately after an injection, as increased body temperature and blood flow can accelerate the absorption of the allergen.
Pulsatilla Patens Whole will interfere with the results of Allergy Skin Testing. If a patient is undergoing immunotherapy, subsequent skin tests for the same allergen will show a modified response (ideally a smaller wheal). It does not typically interfere with standard blood chemistry or hematology tests.
For each major interaction, the mechanism is usually pharmacodynamic (affecting the body's response to the drug or the rescue medication) rather than pharmacokinetic (affecting the drug's metabolism). The clinical consequence is almost always an increased risk of untreated or severe anaphylaxis.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any 'heart' or 'blood pressure' pills.
Conditions where Pulsatilla Patens Whole must NEVER be used include:
Conditions requiring careful risk-benefit analysis:
Patients allergic to Pulsatilla Patens Whole may show cross-sensitivity to other members of the Ranunculaceae family, such as Anemone, Ranunculus (Buttercups), or Clematis. This is due to shared protein structures (homologous allergens) across these genera.
> Important: Your healthcare provider will evaluate your complete medical history, including your lung function and current medications, before prescribing Pulsatilla Patens Whole.
Pulsatilla Patens Whole is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. The primary risk is not the extract itself, but the potential for a systemic allergic reaction (anaphylaxis) in the mother. Anaphylaxis can cause a sudden drop in maternal blood pressure and uterine contraction, leading to fetal distress, miscarriage, or premature labor.
It is not known whether the components of Pulsatilla Patens Whole are excreted in human milk. However, because the allergenic proteins are large and administered in minute quantities, it is highly unlikely that they would reach the infant in significant amounts or survive the infant's digestive process. Breastfeeding is generally considered safe for women receiving immunotherapy.
Immunotherapy is widely used in children as young as 5 years old. It is particularly valued in pediatrics because it may prevent the 'allergic march'—the progression from allergic rhinitis to asthma. Safety and efficacy are similar to adults, but children must be monitored closely for signs of a reaction that they may not be able to verbalize.
Patients over age 65 may receive Pulsatilla Patens Whole, but the physician must carefully evaluate their cardiovascular status. The risk of using epinephrine in an elderly patient with potential coronary artery disease must be weighed against the benefits of allergy treatment. Dose escalation may be performed more slowly in this population.
No dosage adjustments are formally recommended for patients with renal impairment. The allergenic proteins are primarily broken down by cellular proteases rather than being cleared unchanged by the kidneys. However, severe renal disease may affect a patient's overall ability to recover from a systemic reaction.
No dosage adjustments are required for hepatic impairment. The liver's metabolic enzymes (CYP450) are not involved in the processing of allergenic extracts.
> Important: Special populations require individualized medical assessment and often a more cautious approach to dose escalation.
Pulsatilla Patens Whole acts as an immunomodulator. Its primary molecular mechanism involves the induction of peripheral immune tolerance. Upon repeated subcutaneous exposure, the extract interacts with dendritic cells, which then present the allergenic peptides to T-cells. This process promotes the differentiation of T-regulatory (Treg) cells. These Tregs produce Interleukin-10 (IL-10) and Transforming Growth Factor-beta (TGF-β), which suppress the Th2-driven allergic response and inhibit mast cell degranulation. Additionally, there is a marked increase in IgG4 antibodies, which act as 'decoy' receptors for the allergen, preventing it from binding to IgE on mast cells.
The pharmacodynamic effect of Pulsatilla Patens Whole is not immediate. While a skin test shows a reaction within 15-20 minutes, the therapeutic effect (desensitization) takes months to develop. The duration of effect is long-lasting; many patients maintain their 'tolerance' for years after a 3-to-5-year course of treatment. Tolerance development is characterized by a decrease in the 'late-phase' allergic reaction and a reduction in tissue-specific inflammation.
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Subcutaneous/Local) |
| Protein Binding | Primarily to IgE and IgG4 antibodies |
| Half-life | Days (Proteins), Years (Immunological memory) |
| Tmax | 30-60 minutes (Systemic absorption of proteins) |
| Metabolism | Proteolytic degradation by tissue proteases |
| Excretion | Renal (Metabolites) |
Pulsatilla Patens Whole is a complex mixture of proteins, glycoproteins, and polysaccharides. The primary active constituents are the allergenic proteins found in the plant tissues. It is prepared as a sterile solution, often containing 0.5% phenol as a preservative and potentially sodium chloride for isotonicity. The molecular weight of the allergenic proteins typically ranges from 10 to 70 kDa.
Pulsatilla Patens Whole is a Non-Standardized Plant Allergenic Extract. It is related to other plant extracts like Ambrosia artemisiifolia (Ragweed) and Phleum pratense (Timothy Grass), although those are often available in standardized forms.
Common questions about Pulsatilla Patens Whole
Pulsatilla Patens Whole is primarily used as an allergenic extract for the diagnosis and treatment of specific allergies. In a clinical setting, it is used in skin prick testing to determine if a patient is allergic to the Eastern Pasqueflower plant. If an allergy is confirmed and symptoms are severe, the extract is used in allergen immunotherapy, commonly known as allergy shots. This process involves giving gradually increasing doses of the extract to desensitize the immune system. The goal is to reduce the patient's symptoms when they are naturally exposed to the plant in the environment.
The most common side effects are localized reactions at the site of the injection. These include redness, itching, and swelling, which usually appear shortly after the injection and resolve within a few hours. Some patients may also experience a 'large local reaction' where the swelling exceeds several centimeters in diameter. While these are uncomfortable, they are generally not dangerous. However, they are important to report to your doctor as they may influence the size of your next dose.
It is generally recommended to avoid alcohol for several hours before and after receiving an injection of Pulsatilla Patens Whole. Alcohol causes vasodilation, which is the widening of blood vessels. This increased blood flow can potentially cause the allergenic extract to be absorbed into your system more quickly, which might increase the risk or severity of a systemic allergic reaction. To ensure the highest level of safety during your immunotherapy, it is best to remain sober on the day of your treatment.
Pulsatilla Patens Whole is generally not started during pregnancy because of the risk of anaphylaxis, which can be dangerous for both the mother and the developing fetus. However, if a woman is already on a stable maintenance dose of immunotherapy and becomes pregnant, many allergists will continue the treatment at that same dose. The primary concern is the safety of the mother; if she has a severe reaction, it can cut off oxygen to the baby. Always inform your allergist immediately if you become pregnant while receiving these injections.
Allergen immunotherapy is a slow process and does not provide immediate relief like an antihistamine would. Most patients begin to notice a reduction in their allergy symptoms during the 'maintenance phase,' which usually occurs 3 to 6 months after starting the injections. Significant improvement is typically seen after one full year of treatment. For the best long-term results and potential 'cure' of the allergy, a full course of treatment usually lasts between 3 and 5 years.
Yes, you can stop taking Pulsatilla Patens Whole suddenly without experiencing physical withdrawal symptoms. Unlike some medications, your body does not become dependent on allergenic extracts. However, if you stop the treatment before the recommended 3-to-5-year course is complete, your allergy symptoms are very likely to return to their original severity. If you are considering stopping your injections due to side effects or scheduling conflicts, you should first discuss your concerns with your healthcare provider.
If you miss a scheduled injection, you should contact your allergist's office as soon as possible to reschedule. Do not simply wait until your next regular appointment. Depending on how long it has been since your last shot, your doctor may need to reduce the dose for your next injection to ensure safety. Missing multiple doses can result in a loss of the progress you've made in desensitizing your immune system, and you may need to restart at a lower concentration.
There is no clinical evidence to suggest that Pulsatilla Patens Whole or other allergenic extracts cause weight gain. These extracts are proteins that work locally and on the immune system; they do not affect your metabolism, appetite, or hormones in the way that medications like prednisone or certain antidepressants might. If you experience unexpected weight gain while on immunotherapy, it is likely due to other factors and should be discussed with your primary care physician.
Pulsatilla Patens Whole can be taken with many medications, but there are critical exceptions. You must avoid beta-blockers, which are often used for high blood pressure or heart conditions, because they interfere with the treatment of allergic reactions. Other medications like ACE inhibitors and MAOIs may also pose risks. Most standard allergy medications, such as antihistamines and nasal sprays, are safe and often encouraged during the initial phases of immunotherapy. Always provide your doctor with a complete list of your current medications.
The concept of 'generic' vs. 'brand name' is slightly different for allergenic extracts compared to synthetic pills. Pulsatilla Patens Whole is a biological product, and various laboratories may produce their own versions of the extract. While they are essentially the same active ingredient, they are not always interchangeable because they are non-standardized. If you switch clinics, your new doctor will likely perform a new skin test and start your dosing from a safe, low level rather than assuming the extracts are identical.